Morepen Laboratories Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.41 as of 30 Apr 15:30 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Remus Pharmaceuticals Ltd changed from 49.4 on March 2024 to 45.4 on March 2025 . This represents a CAGR of -4.13% over 2 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Remus Pharmaceuticals Ltd changed from ₹ 1016 crore on March 2024 to ₹ 1319 crore on March 2025 . This represents a CAGR of 13.93% over 2 years The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The revenue of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The ebitda of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Remus Pharmaceuticals Ltd?

Market cap of Morepen Laboratories Ltd is 2,269 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd?

As of May 3, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.41. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.